Intec Pharma Ltd. (NTEC)
Stock Price:
$0.408 USD
0.020 (5.05%)
Updated Aug 7, 2020 3:39 PM EDT - Market closed
Key Info
| Market Cap |
28.27M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-33.75M |
| Shares Out |
69.27M |
| EPS (ttm) |
-1.10 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 7, 2020 |
| Last Price |
$0.408 |
| Previous Close |
$0.389 |
| Change ($) |
0.020 |
| Change (%) |
5.05% |
| Day's Open |
0.390 |
| Day's Range |
0.385 - 0.440 |
| Day's Volume |
9,350,612 |
| 52-Week Range |
0.132 - 1.560 |
More Stats
| Market Cap |
28.27M |
| Enterprise Value |
15.00M |
| Earnings Date (est) |
Nov 11, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
69.27M |
| Float |
56.40M |
| EPS (basic) |
-0.92 |
| EPS (diluted) |
-1.10 |
| FCF / Share |
-0.30 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.31M |
| Short Ratio |
0.48 |
| Short % of Float |
2.57% |
| Beta |
0.74 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
2.01 |
| Revenue |
n/a |
| Operating Income |
-33.02M |
| Net Income |
-33.75M |
| Free Cash Flow |
-18.91M |
| Net Cash |
13.26M |
| Net Cash / Share |
0.19 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-42.80% |
| ROE |
-139.99% |
| ROIC |
-687.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (2)
| Buy |
0 |
| Overweight |
0 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
0 |
Low
0.20
Current: $0.408
High
0.20
Target: 0.20
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|
| Revenue | - | - | - | - | - | - |
| Operating Income | -47.11 | -43.33 | -29.44 | -13.81 | -7.58 | -5.78 |
| Net Income | -47.60 | -43.54 | -28.91 | -13.36 | -7.18 | -6.50 |
| Shares Outstanding | 33.78 | 31.19 | 17.66 | 11.45 | - | - |
| Earnings Per Share | -1.41 | -1.40 | -1.64 | -1.17 | -0.92 | -1.18 |
| Operating Cash Flow | -29.05 | -39.08 | -22.13 | -12.01 | -7.93 | -4.75 |
| Capital Expenditures | -0.92 | -4.67 | -4.99 | -0.48 | -1.38 | -0.08 |
| Free Cash Flow | -29.97 | -43.74 | -27.13 | -12.49 | -9.32 | -4.83 |
| Cash & Equivalents | 10.06 | 40.58 | 55.22 | 18.29 | 30.74 | 7.82 |
| Total Debt | 0.80 | - | - | - | - | - |
| Net Cash / Debt | 9.26 | 40.58 | 55.22 | 18.29 | 30.74 | 7.82 |
| Assets | 21.28 | 61.51 | 64.55 | 24.72 | 37.17 | 12.50 |
| Liabilities | 9.75 | 7.97 | 5.75 | 2.02 | 1.64 | 3.02 |
| Book Value | 11.54 | 53.55 | 58.80 | 22.70 | 35.53 | 9.48 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Intec Pharma Ltd. |
| Country |
Israel |
| Employees |
38 |
| CEO |
Jeffrey A. Meckler |
Stock Information
| Ticker Symbol |
NTEC |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: NTEC |
Description
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various indications, including low back pain, neuropathic pain, and fibromyalgia. Intec Pharma Ltd. has a research collaboration agreement with Merck to explore using the Accordion Pill platform for development program. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd. in March 2004. Intec Pharma Ltd. was founded in 2000 and is based in Jerusalem, Israel.